US Stock Movement | Eli Lilly continues to hit historical highs, positive results from clinical research on new weight loss drugs

On November 12th (Wednesday), Eli Lilly rose nearly 3%, continuing to set a new historical high.

In terms of news:

Eli Lilly announced positive results from the Phase 2 clinical trial of its experimental weight loss drug eloralintide. At week 48, all dosage groups of eloralintide achieved the primary endpoint, with an average weight reduction of 9.5% to 20.1%, outperforming the placebo group's average reduction of 0.4% (using efficacy estimation targets). Based on these trial results, Eli Lilly will initiate enrollment for the Phase 3 clinical trial of eloralintide for obesity treatment next month